Page last updated: 2024-12-07

rac-glycerol 1-monodecanoate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

rac-glycerol 1-monodecanoate: a monoglyceride of capric acid [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-monodecanoylglycerol : A 1-monoglyceride that has decanoyl (capryl) as the acyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

rac-1-monodecanoylglycerol : A rac-1-monoacylglycerol composed of equal amounts of 3-decanoyl-sn-glycerol and 1-decanoyl-sn-glycerol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID92926
CHEMBL ID1595008
CHEBI ID75547
CHEBI ID75551
SCHEMBL ID25295
MeSH IDM0045196

Synonyms (76)

Synonym
MLS001076342
c13h26o4
monocaprin
MLS000069539 ,
smr000058599
decanoin, 1-mono-
decanoic acid, 2,3-dihydroxypropyl ester
2,3-dihydroxypropyl decanoate
glyceryl caprate
rac-glycerol 1-monodecanoate
26402-22-2
1-monodecanoyl glycerol
glycerol alpha-monodecanoate
M1072
NCGC00247047-01
NCGC00247047-02
1-monocaprylglycerol
rac-1-decanoylglycerol
rac-2,3-dihydroxypropyl decanoate
rac-1-monodecanoylglycerol
1-monodecanoylglycerol
CHEBI:75547
1-decanoylglycerol
rac-1-monocaprylglycerol
mg 10:0
(+-)-2,3-dihydroxypropyl decanoate
HMS2231D08
decanoic acid, monoester with glycerol
2277-23-8
glyceryl monocaprate
einecs 247-667-6
glycerol 1-monocaprinate
1-monocaprin
197m6vfc1w ,
monoctanoin component b
unii-197m6vfc1w
decanoic acid, monoester with 1,2,3-propanetriol
AKOS016011224
glyceryl 1-caprate
decanoin, mono-
1-decanoyl-rac-glycerol
CHEMBL1595008 ,
chebi:75551 ,
glyceryl-1-caprate
monodecanoin
bdbm50357392
FT-0607795
S6867
HMS3374D10
1,2,3-propanetriol decanoic acid monoester
glyceryl caprate [inci]
SCHEMBL25295
glycerol 1-monodecanoate
LKUNXBRZDFMZOK-UHFFFAOYSA-N
.alpha.-monocaprin
capric acid .alpha.-monoglyceride
decanoic acid 1-monoglyceride
2,3-dihydroxypropyl decanoate #
1-decanoyl-rac-glycerol, analytical standard
OPERA_ID_1770
11139-88-1
1-glyceryl caprate
mfcd00056656
1-decanoyl-rac-glycerol, >=99%
J-016411
DS-6601
DTXSID40891378
mag 10:0
glycerol monocaprate
Q27105050
HY-135117
CS-0109429
glyceryl monocaprate (monocaprin)
F14997
CS-0152259
BP-29816

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"This study explores the potential of the monoglyceride monocaprin as an enhancer of the epithelial permeability of the beta(3)-adrenoceptor agonist BTA-243, as an approach to improving the bioavailability of this drug."( Influence of monocaprin on the permeability of a diacidic drug BTA-243 across Caco-2 cell monolayers and everted gut sacs.
Attwood, D; Brown, JR; Collett, JH; Ley, RW; Sims, EE, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
rac-1-monoacylglycerolA racemate that is composed of equal amounts of 1-acyl-sn-glycerol and 3-acyl-sn-glycerol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency17.78280.044717.8581100.0000AID485294
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency19.95265.623417.292931.6228AID485281
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency19.95260.28189.721235.4813AID2326
chromobox protein homolog 1Homo sapiens (human)Potency56.23410.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency16.32370.004611.374133.4983AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dual specificity protein phosphatase 3Homo sapiens (human)IC50 (µMol)98.20004.00005.97508.5000AID630399
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
MAPK cascadeTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
dephosphorylationDual specificity protein phosphatase 3Homo sapiens (human)
negative regulation of cell migrationDual specificity protein phosphatase 3Homo sapiens (human)
peptidyl-tyrosine dephosphorylationDual specificity protein phosphatase 3Homo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayDual specificity protein phosphatase 3Homo sapiens (human)
negative regulation of MAPK cascadeDual specificity protein phosphatase 3Homo sapiens (human)
positive regulation of mitotic cell cycleDual specificity protein phosphatase 3Homo sapiens (human)
negative regulation of JNK cascadeDual specificity protein phosphatase 3Homo sapiens (human)
negative regulation of T cell receptor signaling pathwayDual specificity protein phosphatase 3Homo sapiens (human)
negative regulation of T cell activationDual specificity protein phosphatase 3Homo sapiens (human)
negative regulation of chemotaxisDual specificity protein phosphatase 3Homo sapiens (human)
regulation of focal adhesion assemblyDual specificity protein phosphatase 3Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeDual specificity protein phosphatase 3Homo sapiens (human)
cellular response to epidermal growth factor stimulusDual specificity protein phosphatase 3Homo sapiens (human)
positive regulation of focal adhesion disassemblyDual specificity protein phosphatase 3Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityDual specificity protein phosphatase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
protein tyrosine phosphatase activityDual specificity protein phosphatase 3Homo sapiens (human)
protein bindingDual specificity protein phosphatase 3Homo sapiens (human)
cytoskeletal protein bindingDual specificity protein phosphatase 3Homo sapiens (human)
protein tyrosine/serine/threonine phosphatase activityDual specificity protein phosphatase 3Homo sapiens (human)
phosphatase activityDual specificity protein phosphatase 3Homo sapiens (human)
myosin phosphatase activityDual specificity protein phosphatase 3Homo sapiens (human)
protein kinase bindingDual specificity protein phosphatase 3Homo sapiens (human)
receptor tyrosine kinase bindingDual specificity protein phosphatase 3Homo sapiens (human)
MAP kinase phosphatase activityDual specificity protein phosphatase 3Homo sapiens (human)
protein tyrosine kinase bindingDual specificity protein phosphatase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
nucleoplasmTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
microtubule cytoskeletonTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
mitotic spindleTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
immunological synapseDual specificity protein phosphatase 3Homo sapiens (human)
nucleusDual specificity protein phosphatase 3Homo sapiens (human)
nucleoplasmDual specificity protein phosphatase 3Homo sapiens (human)
cytosolDual specificity protein phosphatase 3Homo sapiens (human)
cytosolDual specificity protein phosphatase 3Homo sapiens (human)
cytoplasmDual specificity protein phosphatase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID630398Inhibition of GST-tagged human SHP2 N-terminal SH2 domain deficient mutant PTP activity using pNpp as substrate after 30 mins2011Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22
Fatty acids as natural specific inhibitors of the proto-oncogenic protein Shp2.
AID681134TP_TRANSPORTER: Daunomycin accumulation in Caco-2 cells2004British journal of pharmacology, Oct, Volume: 143, Issue:3
Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells.
AID630402Inhibition of GST-tagged human HePTP using pNpp as substrate after 30 mins2011Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22
Fatty acids as natural specific inhibitors of the proto-oncogenic protein Shp2.
AID630399Inhibition of GST-tagged human VHR using pNpp as substrate after 30 mins2011Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22
Fatty acids as natural specific inhibitors of the proto-oncogenic protein Shp2.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.86)18.7374
1990's3 (8.57)18.2507
2000's15 (42.86)29.6817
2010's13 (37.14)24.3611
2020's3 (8.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.59 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index5.23 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (5.71%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (94.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]